Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Dermatitis, Atopic | 20 | 2021 | 714 | 4.44 | Why? |
| Receptors, Histamine H4 | 6 | 2018 | 7 | 2.27 | Why? |
| Eczema | 4 | 2019 | 227 | 1.46 | Why? |
| Allergens | 8 | 2019 | 728 | 1.35 | Why? |
| Ribonucleases | 2 | 2017 | 89 | 1.33 | Why? |
| Th2 Cells | 3 | 2018 | 680 | 1.17 | Why? |
| Receptors, Complement | 2 | 2018 | 15 | 1.09 | Why? |
| Skin | 6 | 2019 | 2096 | 1.08 | Why? |
| Receptors, Interleukin-4 | 2 | 2018 | 11 | 0.96 | Why? |
| Histamine Agonists | 2 | 2018 | 2 | 0.91 | Why? |
| Macrophages | 3 | 2018 | 2784 | 0.90 | Why? |
| GATA3 Transcription Factor | 2 | 2017 | 16 | 0.90 | Why? |
| Dermatitis, Allergic Contact | 3 | 2018 | 185 | 0.81 | Why? |
| Betula | 1 | 2018 | 10 | 0.78 | Why? |
| Toll-Like Receptor 9 | 2 | 2017 | 72 | 0.77 | Why? |
| Immunoglobulin E | 2 | 2019 | 557 | 0.76 | Why? |
| Keratinocytes | 2 | 2017 | 119 | 0.74 | Why? |
| Intermediate Filament Proteins | 1 | 2017 | 9 | 0.73 | Why? |
| Receptors, Histamine H2 | 1 | 2017 | 9 | 0.72 | Why? |
| Pyrimidines | 4 | 2018 | 1557 | 0.71 | Why? |
| Chemokine CCL4 | 1 | 2018 | 71 | 0.71 | Why? |
| S100 Proteins | 1 | 2017 | 25 | 0.71 | Why? |
| Pollen | 1 | 2018 | 137 | 0.70 | Why? |
| Chemokine CCL17 | 1 | 2017 | 30 | 0.69 | Why? |
| Pyrrolidines | 2 | 2018 | 558 | 0.68 | Why? |
| Histamine Antagonists | 1 | 2018 | 203 | 0.67 | Why? |
| Connective Tissue Diseases | 1 | 2019 | 187 | 0.66 | Why? |
| Interleukin-4 | 1 | 2018 | 367 | 0.64 | Why? |
| Anti-Allergic Agents | 1 | 2018 | 167 | 0.63 | Why? |
| Gene Expression Regulation | 3 | 2017 | 4020 | 0.63 | Why? |
| Desensitization, Immunologic | 3 | 2020 | 574 | 0.61 | Why? |
| Phosphodiesterase 4 Inhibitors | 1 | 2017 | 112 | 0.61 | Why? |
| Skin Diseases | 4 | 2020 | 2509 | 0.60 | Why? |
| Dendritic Cells | 2 | 2017 | 1330 | 0.54 | Why? |
| Cyclosporine | 1 | 2018 | 449 | 0.53 | Why? |
| Food Hypersensitivity | 2 | 2018 | 397 | 0.52 | Why? |
| Internal Medicine | 1 | 2019 | 557 | 0.51 | Why? |
| Psoriasis | 2 | 2017 | 1739 | 0.50 | Why? |
| Hypersensitivity | 3 | 2018 | 1137 | 0.50 | Why? |
| Autoimmunity | 1 | 2019 | 841 | 0.47 | Why? |
| Textiles | 1 | 2017 | 458 | 0.46 | Why? |
| DNA | 1 | 2017 | 778 | 0.46 | Why? |
| Interdisciplinary Communication | 1 | 2019 | 1425 | 0.43 | Why? |
| Up-Regulation | 2 | 2018 | 2249 | 0.41 | Why? |
| Microbiota | 1 | 2019 | 1240 | 0.37 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.36 | Why? |
| Immunotherapy | 3 | 2018 | 2421 | 0.35 | Why? |
| Autoantibodies | 1 | 2019 | 2094 | 0.35 | Why? |
| Eye Diseases | 1 | 2019 | 1150 | 0.34 | Why? |
| Antibodies, Monoclonal | 5 | 2019 | 8041 | 0.31 | Why? |
| Complement C3a | 1 | 2006 | 73 | 0.31 | Why? |
| Receptor, Anaphylatoxin C5a | 1 | 2006 | 77 | 0.31 | Why? |
| Monocytes | 2 | 2018 | 2978 | 0.30 | Why? |
| Antigen-Presenting Cells | 1 | 2006 | 206 | 0.30 | Why? |
| Glucocorticoids | 2 | 2018 | 4431 | 0.29 | Why? |
| Complement C5a | 1 | 2006 | 116 | 0.29 | Why? |
| Piperazines | 2 | 2018 | 445 | 0.29 | Why? |
| Dermatitis | 1 | 2006 | 188 | 0.26 | Why? |
| Down-Regulation | 3 | 2018 | 1416 | 0.25 | Why? |
| T-Lymphocytes | 3 | 2017 | 6670 | 0.25 | Why? |
| Cells, Cultured | 4 | 2018 | 5835 | 0.25 | Why? |
| Cell Differentiation | 2 | 2018 | 1338 | 0.23 | Why? |
| Anaphylaxis | 2 | 2021 | 940 | 0.22 | Why? |
| Patch Tests | 3 | 2018 | 114 | 0.22 | Why? |
| Blepharitis | 1 | 2019 | 4 | 0.21 | Why? |
| Anti-Inflammatory Agents | 2 | 2018 | 6153 | 0.21 | Why? |
| Information Services | 2 | 2018 | 70 | 0.20 | Why? |
| Interleukin-4 Receptor alpha Subunit | 1 | 2019 | 46 | 0.20 | Why? |
| Pruritus | 2 | 2018 | 215 | 0.19 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.19 | Why? |
| Erysipelas | 1 | 2018 | 5 | 0.19 | Why? |
| Patient Education as Topic | 3 | 2018 | 1476 | 0.19 | Why? |
| Neurodermatitis | 1 | 2018 | 2 | 0.19 | Why? |
| Receptors, Interleukin-13 | 1 | 2018 | 4 | 0.19 | Why? |
| Malus | 1 | 2018 | 25 | 0.19 | Why? |
| Dental Technicians | 1 | 2018 | 3 | 0.19 | Why? |
| Receptors, Interleukin | 1 | 2018 | 83 | 0.19 | Why? |
| Acrylates | 1 | 2018 | 34 | 0.18 | Why? |
| Streptococcus | 1 | 2018 | 76 | 0.18 | Why? |
| Estrogen Antagonists | 1 | 2018 | 36 | 0.18 | Why? |
| Histamine | 1 | 2018 | 61 | 0.18 | Why? |
| Pyrilamine | 1 | 2017 | 1 | 0.18 | Why? |
| Keratitis | 1 | 2019 | 102 | 0.18 | Why? |
| Skin Care | 1 | 2018 | 49 | 0.18 | Why? |
| Rubber | 1 | 2017 | 6 | 0.17 | Why? |
| Emollients | 1 | 2018 | 108 | 0.17 | Why? |
| Phenylenediamines | 1 | 2017 | 19 | 0.17 | Why? |
| Dapsone | 1 | 2017 | 59 | 0.17 | Why? |
| Antibodies, Monoclonal, Humanized | 6 | 2019 | 9335 | 0.17 | Why? |
| Azo Compounds | 1 | 2017 | 39 | 0.17 | Why? |
| Interleukin-13 | 1 | 2018 | 204 | 0.17 | Why? |
| Rhinitis, Allergic, Seasonal | 1 | 2018 | 121 | 0.17 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.17 | Why? |
| Respiratory Hypersensitivity | 1 | 2018 | 103 | 0.16 | Why? |
| Histamine H1 Antagonists | 1 | 2017 | 79 | 0.16 | Why? |
| Azathioprine | 1 | 2017 | 161 | 0.16 | Why? |
| Skin Tests | 1 | 2017 | 229 | 0.16 | Why? |
| Pemphigoid, Bullous | 1 | 2017 | 89 | 0.16 | Why? |
| Complement C3 | 1 | 2018 | 271 | 0.15 | Why? |
| Membrane Proteins | 1 | 2006 | 1733 | 0.15 | Why? |
| Immunologic Tests | 1 | 2018 | 445 | 0.15 | Why? |
| Humans | 42 | 2021 | 930598 | 0.15 | Why? |
| Placebos | 1 | 2018 | 629 | 0.15 | Why? |
| Cytokines | 2 | 2017 | 15010 | 0.15 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.14 | Why? |
| Conjunctivitis | 1 | 2019 | 318 | 0.14 | Why? |
| Janus Kinases | 1 | 2018 | 414 | 0.14 | Why? |
| Dermatologic Agents | 2 | 2018 | 489 | 0.14 | Why? |
| Streptococcal Infections | 1 | 2018 | 255 | 0.14 | Why? |
| Digestive System Diseases | 1 | 2019 | 378 | 0.14 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2018 | 782 | 0.14 | Why? |
| RNA, Messenger | 2 | 2018 | 5131 | 0.13 | Why? |
| Off-Label Use | 1 | 2018 | 553 | 0.13 | Why? |
| Single-Blind Method | 1 | 2017 | 1283 | 0.12 | Why? |
| Dermatitis, Occupational | 1 | 2018 | 310 | 0.12 | Why? |
| Quality Indicators, Health Care | 1 | 2018 | 580 | 0.12 | Why? |
| Sulfonamides | 2 | 2018 | 1294 | 0.12 | Why? |
| Purines | 1 | 2018 | 816 | 0.12 | Why? |
| Azetidines | 1 | 2018 | 722 | 0.12 | Why? |
| Interleukins | 1 | 2018 | 762 | 0.12 | Why? |
| Janus Kinase Inhibitors | 1 | 2018 | 682 | 0.12 | Why? |
| Belgium | 1 | 2018 | 2064 | 0.12 | Why? |
| Poland | 1 | 2018 | 2368 | 0.11 | Why? |
| Consensus | 3 | 2018 | 6345 | 0.09 | Why? |
| Immunization | 1 | 2018 | 2019 | 0.09 | Why? |
| Kidney Diseases | 1 | 2019 | 1434 | 0.09 | Why? |
| Pyrazoles | 1 | 2018 | 1791 | 0.09 | Why? |
| Adult | 13 | 2021 | 244371 | 0.09 | Why? |
| Apoptosis | 1 | 2018 | 2335 | 0.08 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.08 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.08 | Why? |
| Chemotaxis | 1 | 2006 | 67 | 0.08 | Why? |
| Methylprednisolone | 1 | 2017 | 2107 | 0.08 | Why? |
| Anaphylatoxins | 1 | 2006 | 34 | 0.08 | Why? |
| Interleukin-5 | 1 | 2006 | 138 | 0.08 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.08 | Why? |
| Germany | 2 | 2018 | 9196 | 0.08 | Why? |
| Interleukin-1 | 1 | 2010 | 438 | 0.08 | Why? |
| Biological Products | 1 | 2021 | 2331 | 0.08 | Why? |
| Female | 16 | 2020 | 380317 | 0.08 | Why? |
| Oligonucleotides | 1 | 2006 | 137 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2019 | 1996 | 0.07 | Why? |
| CpG Islands | 1 | 2006 | 230 | 0.07 | Why? |
| Europe | 5 | 2020 | 12702 | 0.07 | Why? |
| Male | 13 | 2020 | 367725 | 0.07 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.07 | Why? |
| Cardiovascular Diseases | 2 | 2019 | 11497 | 0.07 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Virus Diseases | 1 | 2019 | 3779 | 0.06 | Why? |
| Dermatology | 1 | 2017 | 1999 | 0.06 | Why? |
| Ligands | 1 | 2006 | 1300 | 0.05 | Why? |
| Calcium | 1 | 2006 | 708 | 0.05 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.05 | Why? |
| Asthma | 1 | 2019 | 4383 | 0.05 | Why? |
| Young Adult | 4 | 2018 | 93724 | 0.05 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2018 | 3633 | 0.05 | Why? |
| Subcutaneous Absorption | 1 | 2018 | 4 | 0.05 | Why? |
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2018 | 12 | 0.05 | Why? |
| bcl-X Protein | 1 | 2018 | 19 | 0.05 | Why? |
| Gene Targeting | 1 | 2018 | 34 | 0.05 | Why? |
| Registries | 1 | 2018 | 12327 | 0.05 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.04 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.04 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.04 | Why? |
| Interferon-alpha | 1 | 2006 | 1442 | 0.04 | Why? |
| Aniline Compounds | 1 | 2018 | 120 | 0.04 | Why? |
| Remission, Spontaneous | 1 | 2018 | 186 | 0.04 | Why? |
| Retrospective Studies | 3 | 2018 | 105322 | 0.04 | Why? |
| Ovalbumin | 1 | 2017 | 84 | 0.04 | Why? |
| Administration, Cutaneous | 1 | 2018 | 229 | 0.04 | Why? |
| Epidermis | 1 | 2017 | 47 | 0.04 | Why? |
| Receptors, Estrogen | 1 | 2018 | 171 | 0.04 | Why? |
| Calcineurin Inhibitors | 1 | 2018 | 218 | 0.04 | Why? |
| Phototherapy | 1 | 2018 | 138 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Economics, Pharmaceutical | 1 | 2016 | 61 | 0.04 | Why? |
| Markov Chains | 1 | 2018 | 502 | 0.04 | Why? |
| Middle Aged | 7 | 2018 | 270681 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.04 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.04 | Why? |
| Child | 3 | 2018 | 70012 | 0.04 | Why? |
| Review Literature as Topic | 1 | 2018 | 387 | 0.04 | Why? |
| Face | 1 | 2018 | 301 | 0.04 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.03 | Why? |
| Environmental Pollutants | 1 | 2018 | 320 | 0.03 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.03 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.03 | Why? |
| Decision Support Systems, Clinical | 1 | 2018 | 551 | 0.03 | Why? |
| Quality of Life | 3 | 2018 | 9820 | 0.03 | Why? |
| Immune Tolerance | 1 | 2016 | 608 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.03 | Why? |
| Severity of Illness Index | 4 | 2018 | 48226 | 0.02 | Why? |
| Adaptation, Psychological | 2 | 2018 | 4996 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2018 | 3608 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Aged | 4 | 2018 | 215776 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Mice | 2 | 2018 | 21357 | 0.02 | Why? |
| Cell Communication | 1 | 2010 | 396 | 0.02 | Why? |
| Environmental Exposure | 1 | 2018 | 1558 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.02 | Why? |
| Cell Count | 1 | 2006 | 228 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2016 | 2259 | 0.02 | Why? |
| Diet | 1 | 2018 | 2052 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2017 | 3347 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.02 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 1165 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.01 | Why? |
| Treatment Failure | 1 | 2006 | 2106 | 0.01 | Why? |
| Eosinophils | 1 | 2006 | 848 | 0.01 | Why? |
| Interferon-gamma | 1 | 2010 | 2711 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Animals | 2 | 2018 | 78931 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Infant | 1 | 2018 | 30274 | 0.01 | Why? |
| Antirheumatic Agents | 1 | 2010 | 3023 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Immunologic Factors | 1 | 2010 | 4206 | 0.01 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
Werfel's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(239)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(235)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_